Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
Completed · Phase 4 · Has a placebo group
Conditions studied: Obesity
In brief
The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of off-treatment recovery.
Key facts
- Study ID
- NCT02229214
- Run by
- VIVUS LLC
- People needed
- 51
- Starts
- 2014-08-01
- Expected to finish
- 2014-11-01
- Last updated by the study team
- 2017-11-07
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Research Center — Lakewood, Colorado, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.